Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis

Cytokine. 2018 Nov;111:182-188. doi: 10.1016/j.cyto.2018.08.025. Epub 2018 Aug 29.

Abstract

Psoriasis and psoriatic arthritis cause significant physical and psychological burdens for afflicted individuals. An accelerated TNF-α/IL-23/IL-17 axis is their major pathomechanism; therefore, anti-TNF-α/IL-23/IL-17 biologics are very effective for the treatment of skin and joint lesions in psoriasis and psoriatic arthritis. Given that the IL-17 signature is more upregulated in the skin than in synovium in psoriatic arthritis, anti-IL-23/IL-17 agents seem to be superior to anti-TNF-α remedies in the treatment of skin lesions. In this review, we focus on the differential efficacy of anti-TNF-α/IL-23/IL-17 biologics in psoriasis and psoriatic arthritis.

Keywords: Biologics, efficacy; Psoriasis; Psoriatic arthritis; TNF-α/IL-23/IL-17 axis.

Publication types

  • Review

MeSH terms

  • Arthritis, Psoriatic / metabolism*
  • Humans
  • Interleukin-17 / metabolism*
  • Interleukin-23 / metabolism*
  • Psoriasis / metabolism*
  • Skin / metabolism
  • Tumor Necrosis Factor-alpha / metabolism*

Substances

  • Interleukin-17
  • Interleukin-23
  • Tumor Necrosis Factor-alpha